Global Eisenmenger Complex Management Market to Surpass USD 12.9 Billion by 2033, Growing at 5.3% CAGR

Eisenmenger Complex Management Market

The global Eisenmenger Complex Management Market is poised for significant growth, projected to exceed USD 12.9 Billion by 2033, up from USD 7.7 Billion in 2023, reflecting a steady Compound Annual Growth Rate (CAGR) of 5.3% over the forecast period.

This growth is largely driven by an increase in the number of patients with mild congenital heart diseases (CHDs) and rising investments in research and development for advanced treatment options. Approximately 1 in 4 babies born with congenital heart defects have critical CHDs, many of whom require surgery or medical interventions within the first year of life.

The focus on developing advanced drugs and treatment options for Eisenmenger syndrome, a rare and severe form of CHD, is expected to create lucrative opportunities in the market, supporting continued innovation and improvement in patient outcomes.

The increase in the number of patients suffering from mild congenital heart diseases and the growing focus on research and development activities related to the development of advanced drugs are factors anticipated to drive the growth of the global Eisenmenger syndrome treatment market. About 1 in 4 babies with congenital heart diseases have critical CHDs. Infants with the critical disease generally need surgery or other procedures in their first year of life.

Rising investment by major players for the development of innovative solutions and high spending on healthcare infrastructure development are factors anticipated to create new prospects for players operating in the Eisenmenger syndrome treatment market over the forecast period. In addition, growing partnership and agreements between players in order to improve the business presence is expected to support the revenue growth of the target market.

Market Competition

The global Eisenmenger syndrome treatment market is highly competitive due to the presence of a large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition. The major players in the market are Actelion Pharmaceuticals Ltd, Gilead Sciences, Inc., Pfizer, Inc, Teva Pharmaceutical Industries Ltd, AstraZeneca plc., Novartis AG, Merck and Co., Inc., GlaxoSmithKline plc., Mylan N.V, Bayer AG.

Some recent developments in this industry are:

• In July 2022, Cereno Scientific announced that the first patient had been enrolled in the Phase II study in pulmonary arterial hypertension (PAH) with drug candidate CS1.
• In June 2022, Gossamer Bio, Inc. declared the publication of key preclinical data supporting the potential of seralutinib for the treatment of pulmonary arterial hypertension (PAH).
• In December 2021, Aerovate Therapeutics, a clinical-stage biopharmaceutical company based in the United States, started the Phase 2b/3 clinical trial for testing imatinib, its experimental inhaled formulation in people with Eisenmenger syndrome. The trial is set to help the company in achieving the goal of enhancing the lives of patients suffering from rare cardiovascular diseases. This test will evaluate the ability of AV-101 to resist blood flow in the blood vessels of the lungs.
• In December 2021, Alembic Pharmaceuticals, a multinational pharmaceutical company headquartered in India, bagged approval from the United States Food and Drug Administration (USFDA) for the marketing of Selexipag December 2021, Alembic Pharmaceuticals tablets. These can now be used to treat pulmonary arterial hypertension. The company’s new drug is considered to be the generic equivalent to Uptravi, the Reference Listed Drug (RLD).

Key Companies Profiled

• Actelion Pharmaceuticals Ltd
• Gilead Sciences, Inc.
• Pfizer, Inc
• Teva Pharmaceutical Industries Ltd
• AstraZeneca plc.
• Novartis AG
• Merck and Co., Inc.
• GlaxoSmithKline plc.
• Mylan N.V
• Bayer AG

A Full Report Overview

Key Segments Profiled in the Eisenmenger Complex Management Industry Survey

By Drug Type:

• Antiarrhythmic Agents
• Blood Thinning Agents
• Endothelin Receptor Antagonist
• Others

By Diagnosis:

• Blood tests
• Electrocardiogram
• Chest X-ray
• Echocardiogram
• CT Scan
• MRI
• Cardiac Catheterization

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By End User:

• Hospitals & Clinics
• Laboratories
• Others

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa (MEA)

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube